Spotlight
Topics
DI Executive
Subscribe
- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears AI Software for Assessing Intracerebral Hemorrhage on Non-Contrast CT
Facilitating timely diagnosis and intervention for brain bleeds, the artificial intelligence (AI)-powered Viz ICH Plus software may provide quantified assessment for intracranial hyperdensities, lateral ventricles and midline shifts.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Viz ICH Plus software, which utilizes artificial intelligence (AI) to help quantify intracerebral hemorrhage on non-contrast computed tomography (CT) images.
For cases involving intracerebral hemorrhage, Viz ICH Plus offers automated detection, labeling, and volume quantification for segmentable brain structures, according to Viz.ai, the developer of the software.
The newly FDA-cleared Viz ICH Plus reportedly offers automated detection, labeling and volume quantification of intracerebral hemorrhage on non-contrast CT. (Image courtesy of Viz.ai.)
Given the critical nature of intracerebral hemorrhage, which reportedly accounts for 15 percent of strokes, the capability of Viz ICH Plus software to analyze intracranial hyperdensities, lateral ventricles and midline shifts may improve timely diagnosis and decision-making for appropriate treatments.
"The ability and mobility to obtain accurate and quantifiable measurements of intracerebral hemorrhages through Viz ICH Plus significantly enhances our decision-making process,” said Peter Kan, MD, MPH, FRCSC, FAANS, a professor and chair of the Department of Neurosurgery at the University of Texas Medical Branch. “This technology, which marries precision with AI, is poised to transform how we approach intracerebral hemorrhage cases."
Recent Videos
Related Content
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024Article
A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024Article
The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024Article
For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
